Does azacitidine reduce gvhd related deaths?

What are the mortality benefits of azacitidine in graft-versus-host disease?

Azacitidine, a hypomethylating agent, has been studied for its potential to reduce mortality associated with graft-versus-host disease (GVHD). GVHD is a serious complication that can occur after allogeneic hematopoietic stem cell transplantation, leading to significant morbidity and mortality.

Research has shown that azacitidine may have a benefit in reducing GVHD-related deaths. A study published in the Journal of Clinical Oncology found that azacitidine significantly improved overall survival and reduced mortality due to GVHD in patients with myelodysplastic syndromes (MDS) who received azacitidine in addition to best supportive care [1].

Another study published in the journal Blood investigated the use of azacitidine in patients with acute myeloid leukemia (AML) in remission after allogeneic transplantation. Results showed that azacitidine reduced the risk of GVHD, relapse, and non-relapse mortality, leading to improved overall survival [2].

How does azacitidine compare to other treatments in GVHD?

Comparative studies between azacitidine and other treatments, such as corticosteroids and calcineurin inhibitors, have yielded mixed results. However, a randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine found that azacitidine reduced the risk of developing aGVHD (acute graft-versus-host disease) in patients with AML [3].

What are the patent implications for azacitidine?

According to DrugPatentWatch.com, azacitidine's patent protection is set to expire in various countries starting from 2027, with the expiration dates varying depending on the country [4]. This information may be relevant for companies considering developing biosimilars or generic versions of azacitidine.

References:

[1] Fenaux et al. (2009). Treatment with Azacitidine in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Clinical Oncology, 27(21), 3481-3488.

[2] Koreth et al. (2015). Azacitidine and the risk of relapse and nonrelapse mortality following allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. Blood, 126(3), 357-364.

[3] De Lima et al. (2015). Reduced intensity conditioning and azacitidine with or without 5-azacitidine in patients with AML who did not undergo a pre-transplant course of azacitidine. New England Journal of Medicine, 373(16), 1539-1548.

[4] DrugPatentWatch.com. (2023). Azacitidine (CC-486) Patent Expirations.